- Chemotherapy
- Adjuvant Chemotherapy
- Radiation Therapy
- Surgery
- Targeted Therapy
Gastric Cancer Treatment Market size was valued at USD 9.5 billion in 2022. It is expected to reach USD 25.6 billion by 2028, at a CAGR of 15.3% from 2023 to 2029. Sacral nerve stimulation (SNS) is a therapeutic electrical incitement treatment that is utilized to treat long-haul entrail control and bladder control side effects through the adjustment of nerves controlling the lower urinary tract and pelvic floor. The gastric cancer market is becoming quickly because of expanding occurrence of adenocarcinoma, lymphoma and gastrointestinal stromal tumors over the globe. Significant drivers for the Gastric Cancer Market are treatment progressions, combination therapies, expanding the number of growth treatment focuses, the extensive number of regulatory approvals for metastatic gastric disease and low-measurement radiation innovation-based devices. Moreover, the introduction of novel treatments for metastatic stomach disease is relied upon to drive the development of the Gastric Cancer market soon. However, the absence of sufficient monetary help from medical coverage strategies and stringent regulatory framewok for approving complex nature of radiation devices are the main considerations that can hamper the stomach malignancy advertise development over the figure time frame. Different factors, like, high cost of therapy and monetarily less accessibility of medications for the treatment of Gastric Cancer may hamper the worldwide high cost of therapy.
Gastric Cancer Treatment Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
15.3%
Largest Market
North-America
Fastest Growing Market
Asia-Pacific
Gastric Cancer Treatment Market Dynamics
Currently, the products available in the market constitutes of a broad assortment of treatment choices, for example, angiogenesis inhibitors, new chemotherapies and HER2-focused on therapy. The worldwide gastric cancer treatment market is becoming quickly attributable to the high extent of people with gastric cancer and the nearness of a solid medication pipeline. To pick up footing in this market, the sellers are assembling and marketing gastric cancer drugs hat display a high wellbeing and adequacy profile, this causes the merchants to pick up a focused edge over their peers. In February 2018, Imugene, an invulnerable oncology organization declared that its malignancy immunization yields promising outcomes in gastric disease clinical preliminary examinations and in September 2017, The Food and Drug Administration (FDA) approved the immunotherapy drug pembrolizumab (Keytruda®) to be utilized on patients with cutting edge gastric cancer growth.
Asia-Pacific Got Significant Share Of
Gastric Cancer Treatment Market Regional Analysis
Geographically Gastric Cancer Treatment Market is segmented as Latin America, North America, Asia- Pacific, The Middle East & Africa and Europe. Asia-Pacific overwhelms the worldwide gastric cancer treatment market, due high incidence rate of gastric cancer treatment in that locale. China is relied upon to demonstrate a huge development for this market, amid the forecast period, attributable to factors, such as high commonness of obesity and developing awareness about diabetes care. The developing frequency of market in China is followed by Japan and Korea. China represents more than 40% of all new gastric disease cases on earth, which will drive the market for gastric cancer treatment market in China. Different regions who have a high number of gastric growth patients are North America and Europe, which are anticipated to hold a solid position in the market. There is a high utilization of gastric disease medications, for example, Afinitor, Herceptin, and Erbitux that could expand their request in Europe and North America.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The gastric cancer treatment market report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Gastric Cancer Treatment Market Segmentation
By Treatment Type
By Cancer Type
- Laryngeal Cancer
- Lip and Oral Cavity Cancer
- Nasopharyngeal Cancer
- Oropharyngeal Cancer
- Salivary Gland Cancer
- Others
Frequently Asked Questions
The gastric cancer treatment market is projected to expand at a CAGR of 15.3% during the forecast period
Abbott Laboratories, AstraZeneca plc, Eli Lilly and Company, Hoffmann-La Roche Ltd, Pfizer, Inc.
North America is the fastest-growing region for gastric cancer treatment market
| 1.Executive Summary |
| 2.Global Gastric Cancer Treatment Market Introduction |
| 2.1.Global Gastric Cancer Treatment Market - Taxonomy |
| 2.2.Global Gastric Cancer Treatment Market - Definitions |
| 2.2.1. By Treatment Type |
| 2.2.2. By Cancer Type |
| 2.2.3. By End User |
| 2.2.4. By Region |
| 3.Global Gastric Cancer Treatment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Gastric Cancer Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Gastric Cancer Treatment Market By Treatment Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 5.1. Chemotherapy |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Adjuvant Chemotherapy |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Radiation Therapy |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Surgery |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Targeted Therapy |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 6.Global Gastric Cancer Treatment Market By Cancer Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 6.1. Laryngeal Cancer |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Lip and Oral Cavity Cancer |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Nasopharyngeal Cancer |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Oropharyngeal Cancer |
| 6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Salivary Gland Cancer |
| 6.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 6.6. Others |
| 6.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.6.3. Market Opportunity Analysis |
| 7.Global Gastric Cancer Treatment Market By End User, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Ambulatory Surgical Centers |
| 7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Specialized Cancer Treatment Centers |
| 7.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Gastric Cancer Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia Pacific (APAC) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Middle East and Africa (MEA) |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Latin America |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
| 8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 9.North America Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 9.1. Treatment Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Chemotherapy |
| 9.1.2.Adjuvant Chemotherapy |
| 9.1.3.Radiation Therapy |
| 9.1.4.Surgery |
| 9.1.5.Targeted Therapy |
| 9.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Laryngeal Cancer |
| 9.2.2.Lip and Oral Cavity Cancer |
| 9.2.3.Nasopharyngeal Cancer |
| 9.2.4.Oropharyngeal Cancer |
| 9.2.5.Salivary Gland Cancer |
| 9.2.6.Others |
| 9.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Hospitals |
| 9.3.2.Clinics |
| 9.3.3.Ambulatory Surgical Centers |
| 9.3.4.Specialized Cancer Treatment Centers |
| 9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.4.1.United States of America (USA) |
| 9.4.2.Canada |
| 10.Europe Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 10.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Chemotherapy |
| 10.1.2.Adjuvant Chemotherapy |
| 10.1.3.Radiation Therapy |
| 10.1.4.Surgery |
| 10.1.5.Targeted Therapy |
| 10.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Laryngeal Cancer |
| 10.2.2.Lip and Oral Cavity Cancer |
| 10.2.3.Nasopharyngeal Cancer |
| 10.2.4.Oropharyngeal Cancer |
| 10.2.5.Salivary Gland Cancer |
| 10.2.6.Others |
| 10.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Hospitals |
| 10.3.2.Clinics |
| 10.3.3.Ambulatory Surgical Centers |
| 10.3.4.Specialized Cancer Treatment Centers |
| 10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Germany |
| 10.4.2.France |
| 10.4.3.Italy |
| 10.4.4.United Kingdom (UK) |
| 10.4.5.Spain |
| 11.Asia Pacific (APAC) Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 11.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Chemotherapy |
| 11.1.2.Adjuvant Chemotherapy |
| 11.1.3.Radiation Therapy |
| 11.1.4.Surgery |
| 11.1.5.Targeted Therapy |
| 11.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Laryngeal Cancer |
| 11.2.2.Lip and Oral Cavity Cancer |
| 11.2.3.Nasopharyngeal Cancer |
| 11.2.4.Oropharyngeal Cancer |
| 11.2.5.Salivary Gland Cancer |
| 11.2.6.Others |
| 11.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Hospitals |
| 11.3.2.Clinics |
| 11.3.3.Ambulatory Surgical Centers |
| 11.3.4.Specialized Cancer Treatment Centers |
| 11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.China |
| 11.4.2.India |
| 11.4.3.Australia and New Zealand (ANZ) |
| 11.4.4.Japan |
| 11.4.5.Rest of APAC |
| 12.Middle East and Africa (MEA) Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 12.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Chemotherapy |
| 12.1.2.Adjuvant Chemotherapy |
| 12.1.3.Radiation Therapy |
| 12.1.4.Surgery |
| 12.1.5.Targeted Therapy |
| 12.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Laryngeal Cancer |
| 12.2.2.Lip and Oral Cavity Cancer |
| 12.2.3.Nasopharyngeal Cancer |
| 12.2.4.Oropharyngeal Cancer |
| 12.2.5.Salivary Gland Cancer |
| 12.2.6.Others |
| 12.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Hospitals |
| 12.3.2.Clinics |
| 12.3.3.Ambulatory Surgical Centers |
| 12.3.4.Specialized Cancer Treatment Centers |
| 12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.GCC Countries |
| 12.4.2.South Africa |
| 12.4.3.Rest of MEA |
| 13.Latin America Gastric Cancer Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
| 13.1. Treatment Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Chemotherapy |
| 13.1.2.Adjuvant Chemotherapy |
| 13.1.3.Radiation Therapy |
| 13.1.4.Surgery |
| 13.1.5.Targeted Therapy |
| 13.2. Cancer Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Laryngeal Cancer |
| 13.2.2.Lip and Oral Cavity Cancer |
| 13.2.3.Nasopharyngeal Cancer |
| 13.2.4.Oropharyngeal Cancer |
| 13.2.5.Salivary Gland Cancer |
| 13.2.6.Others |
| 13.3. End User Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Hospitals |
| 13.3.2.Clinics |
| 13.3.3.Ambulatory Surgical Centers |
| 13.3.4.Specialized Cancer Treatment Centers |
| 13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Brazil |
| 13.4.2.Mexico |
| 13.4.3.Rest of LA |
| 14. Competition Landscape |
| 14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 14.2.1.Abbott Laboratories, Inc.(U.S) |
| 14.2.2.AstraZeneca plc (U.K) |
| 14.2.3.Eli Lilly and Company(U.S.) |
| 14.2.4.Hoffmann-La Roche Ltd. (Switzerland) |
| 14.2.5.Pfizer, Inc. (U.S.) |
| 14.2.6.GlaxoSmithKline plc (UK) |
| 14.2.7.Amgen, Inc.(U.S) |
| 14.2.8.Celgene corporation (U.S) |
| 14.2.9.Novartis AG (Switzerland) |
| 15. Research Methodology |
| 16. Appendix and Abbreviations |
- Abbott Laboratories, Inc.(U.S)
- AstraZeneca plc (U.K)
- Eli Lilly and Company(U.S.)
- Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer, Inc. (U.S.)
- GlaxoSmithKline plc (UK)
- Amgen, Inc.(U.S)
- Celgene corporation (U.S)
- Novartis AG (Switzerland)